The Protective Arm of the Renin Angiotensin System (RAS) : (Record no. 49836)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11176nam a22005053i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC2030662 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729123550.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2015 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780128014851 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9780128013649 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC2030662 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL2030662 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11047003 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL772156 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)908074996 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | QP572.A54 -- .U544 2015eb |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Unger, Thomas. |
| 245 14 - TITLE STATEMENT | |
| Title | The Protective Arm of the Renin Angiotensin System (RAS) : |
| Remainder of title | Functional Aspects and Therapeutic Implications. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | San Diego : |
| Name of producer, publisher, distributor, manufacturer | Elsevier Science & Technology, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2015. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (312 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Front Cover -- The Protective Arm of the Renin-Angiotensin System: Functional Aspects and Therapeutic Implications -- Copyright -- Contents -- Contributors -- Chapter 1: The Angiotensin AT 2 Receptor: From Enigma to Therapeutic Target -- Introduction -- References -- Chapter 2: The AT 2 Receptor: Historical Perspective -- Background to the Early Involvement of Ciba-Geigy in the Angiotensin Field -- Two Ang II Receptor Subtypes -- Angiotensin II Receptor Nomenclature -- Early Research on the Role of the AT 2 Receptor -- Conclusion -- References -- Chapter 3: Animal Models with a Genetic Alteration of AT 2 Expression -- Introduction -- Blood Pressure -- Cardiac Disease -- Vascular Disease -- Renal Disease -- Neural Disease -- Conclusion -- References -- Chapter 4: AT 2 Receptor Signaling: Solved and Unsolved -- Introduction -- AT 2 R Dimerization -- Proliferation and Differentiation -- Apoptosis -- Inflammation -- Fibrosis -- Solved and Unsolved Issues -- References -- Chapter 5: AT 1 R - AT 2 R Cross Talk -- Cross Regulation of Angiotensin II Type 1 Receptor and the Angiotensin II Type 2 Receptor -- Functional Significance of the AT 1 R - AT 2 R Cross Talk -- Conclusion -- References -- Chapter 6: The Angiotensin AT 2 Receptor in Myocardial Infarction -- Introduction -- AT 2 Receptor Expression in the Heart -- Acute-Phase Postmyocardial Infarction -- Cardiac Function -- Bradykinin/Nitric Oxide System -- Intracellular Acidosis -- Apoptosis -- Inflammation -- Tissue Regeneration -- Late-Phase Postmyocardial Infarction -- Cardiac Function -- Cardiac Fibrosis -- Cardiac Hypertrophy -- Extracellular Matrix Degradation -- Conclusion -- References -- Chapter 7: AT 2 R, Vascular Effects, and Blood Pressure -- Introduction -- AT 2 Vasorelaxation: In Vitro Preclinical Studies -- Acute AT 2 R Vasodilatation/ BP Effects: In Vivo Preclinical Studies. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chronic AT 2 R Effects on BP: Preclinical Studies -- Human Vascular AT 2 R Function: Ex Vivo and In Vivo Studies -- AT 2 R Vasorelaxation: Why Is There no Translation into Antihypertensive Effects in Chronic Studies? -- Acknowledgments -- References -- Chapter 8: AT 2 R in Nervous System -- Introduction -- AT 2 R Expression in CNS -- AT 2 R Expression in Neuronal Injury -- AT 2 R -Mediated Effects in CNS Cells -- AT 2 R in Peripheral Neuronal Injury -- AT 2 R Stimulation in Stroke -- AT 2 R in Spinal Cord Injury -- AT 2 R in Multiple Sclerosis -- AT 2 R in Traumatic Brain Injury -- Conclusion -- References -- Chapter 9: Roles of AT 2 R in Cognitive Function -- Introduction -- Preventive Effects of ARB on Cognitive Decline and Dementia -- Protection Against Ischemic Brain Damage by AT 2 R Stimulation -- Role of AT 2 R Stimulation in Cognitive Function -- Role of AT 2 R-Associated Proteins in Cognitive Function -- Conclusion -- Acknowledgments -- References -- Chapter 10: The Protective Role of Angiotensin II ( AT 2) Receptors in Renal Disease: Molecular Mechanisms and Indications ... -- Introduction -- Renal AT 2 R Expression -- Findings from AT 2 R Knockout ( AT 2 KO) Mice -- AT 2 R -Mediated Signaling Pathways -- Renoprotective Mechanisms of AT 2 R Stimulation -- Inflammation and Oxidative Stress -- Fibrosis and Extracellular Matrix Accumulation -- AT 2 R -Mediated Modulation of Other RAS Components -- Additional Mechanisms Involved in AT 2 R -Mediated Renoprotection -- AT 2 R in Renal Disease Associated with Obesity/Diabetes -- Conclusion -- References -- Chapter 11: AT 2 Receptors and Natriuresis -- Introduction -- Renal Expression of AT 2 Rs -- AT 2 R Induction of Natriuresis: Initial Evidence -- Role of Angiotensin III in AT 2 R -Induced Natriuresis -- Nephron Sites and Mechanisms of AT 2 R -Induced Natriuresis via ANG III. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | AT 2 R -Dopamine D 1 -Like Receptor Interactions -- Physiological Significance of Renal AT 2 Rs in Renal Na + Excretion -- AT 2 R -Induced Natriuresis in Disease States -- AT 2 R Agonist Administration and Natriuresis -- Conclusion -- References -- Chapter 12: The Role of the AT 2 R in Vascular Remodeling -- Introduction -- The Theoretical Concept of the Role of AT 2 R in Vascular Remodeling -- AT 2 R and Hypertension-Induced Vascular Remodeling -- AT 2 R and Atherosclerosis -- AT 2 R and Aortic Aneurysm -- Conclusion -- References -- Chapter 13: The AT 2 Receptor and Inflammation -- Introduction -- AT 2 R Signaling in Inflammation -- Inflammation in Cardiovascular Disease and the Role of the AT 2 Receptor -- Atherosclerosis -- Myocardial Infarction: Heart Failure -- Stroke -- Renal Injury -- Inflammation in Autoimmune Disease and the Role of the AT 2 Receptor -- Conclusions -- References -- Chapter 14: The AT 2 Receptor and Interacting Proteins (ATIPs) in Cancer -- The Renin-Angiotensin System and Cancer -- The AT 2 Receptor and Cancer -- AT 2 Receptor-Interacting Proteins (ATIPs) and Cancer -- Acknowledgments -- References -- Chapter 15: AT 2 R and Sympathetic Outflow -- Introduction -- AT 2 R Ontogeny in Rodent Brain -- Effect of AT 2 R Activation on Neuronal Electrophysiological Characteristics -- AT 2 R and Sympathetic Regulation in Normal States -- Effects of the AT 2 R on Sympathetic Outflow in Pathological Conditions and Therapeutic Potential -- Conclusion and Perspectives -- Acknowledgments -- References -- Chapter 16: Metabolic Effects of AT 2 R Stimulation in Adipose Tissue -- Introduction -- Metabolic Function of AT 2 R: The Lessons from ARBs -- Metabolic Function of AT 2 R: The Lessons from AT 2 R-Deficient Mice -- Metabolic Function of AT 2 R: Experiments with Direct AT 2 R Stimulation -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 17: Sex Differences in AT 2 R Expression and Action -- Basis for Sex Differences in Function -- AT 2 R Gene Mapping -- Hormonal Regulation of AT 2 R Expression -- Regulation of Arterial Pressure and Renal Function -- Arterial Pressure -- Kidney -- Evidence for a Differential Role for the AT 2 R in Other Disease Conditions -- Heart and Vascular Disease -- Neurological Disorders -- Reproduction -- Conclusion -- References -- Chapter 18: Discovery of Nonpeptide, Selective AT 2 Receptor Agonists -- Selective Drug-like AT 2 R Agonists from Nonpeptide, Nonselective AT 1 /AT 2 Receptor Ligands -- Selective Drug-like AT 2 R Agonists from the Nonselective Parent Peptide Ang II -- Conversion of AT 2 R Agonists to AT 2 R Antagonists -- Acknowledgments -- References -- Chapter 19: Angiotensin-Based Peptides as AT 2 R Agonists -- Introduction -- Endogenous Angiotensin Peptides -- Ang II -- Ang III -- Ang IV -- Ang 1-7 -- Ang 1-9 -- Synthetic Peptides -- CGP42112 -- β -Amino-Acid-Substituted Angiotensin Peptides -- [Y] 6 -AII -- LP2-3 (dKcAng-(1-7)) -- Novokinin -- Conclusions -- Acknowledgments -- References -- Chapter 20: Potential Clinical Application of Angiotensin 2 Receptor Agonists -- Introduction -- Preclinical Testing -- Investigational New Drug Application -- Clinical Trials -- Potential Therapeutic Indications for AT 2 R Agonists -- Orphan Indications -- Marfan Syndrome -- Idiopathic Pulmonary Fibrosis -- Other Indications -- Conclusion -- References -- Chapter 21: Angiotensin-(1-7) and Mas: A Brief History -- Introduction -- Discovery of Mas: Is It a Proto-Oncogene? -- Functions of Mas: Is It an Ang II Receptor? -- Mas, Its Antisense RNA, and Imprinting -- Mas Expression -- Mas Functions: Mas-Deficient Mice -- Discovery of Ang-(1-7) -- Closing the Gap: Mas Is an Ang-(1-7) Receptor -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 22: Animal Models with a Genetic Alteration of the ACE2/Ang-(1-7)/Mas Axis -- Introduction -- Transgenic Animal Technology: A Brief Update -- Transgenic and KO Rodent Models of the ACE2/Ang-(1-7)/Mas Axis -- ACE2 Models -- ACE2 KO Mice -- Human ACE2 Overexpression in Mouse -- Human ACE2 Overexpression in the Mouse Brain -- Human ACE2 Overexpression in the Mouse Heart -- Human ACE2 Overexpression in Mouse Podocytes -- Human ACE2 Overexpression in the Rat Vascular Smooth Muscle -- Mas Models -- Mas-KO Mice -- Mas Overexpression in Retina -- Prolylcarboxypeptidase KO Mice -- Ang-(1-7) Models -- Transgenic Rats Overexpressing Ang-(1-7) -- Transgenic Mice and Rats Overexpressing Ang-(1-7) in the Heart -- Conclusions and Outlook -- References -- Chapter 23: Mas Signaling: Resolved and Unresolved Issues -- Introduction -- Expression of Mas -- Mas as a GPCR -- Early Discovery of Mas and Its Signaling Pathways -- Identifying Ang-(1-7) Targets Through Proteomics -- Ang-(1-7)/Mas Signaling Through Akt -- Ang-(1-7)/Mas Signaling and Nitric Oxide Production -- Mas and MAPK Signaling -- Mas and RhoA -- Biological Significance of Mas Signaling: Insights from Mas-Knockout Mice -- Unresolved Issues -- Conclusions -- Acknowledgments -- References -- Chapter 24: Mas/AT 2 Cross Talk -- References -- Chapter 25: ACE2 Cell Biology, Regulation, and Physiological Functions -- Introduction -- ACE2: Discovery and Basic Biology -- ACE2 Regulation -- References -- Chapter 26: Mas in Myocardial Infarction and Congestive Heart Failure -- Myocardial Infarction and Congestive Heart Failure -- Renin-Angiotensin System and Cardiac Remodeling -- Inflammatory Phase -- Proliferative Phase -- Maturation Phase -- References -- Chapter 27: Mas Receptor: Vascular and Blood Pressure Effects -- References -- Chapter 28: Mas and Neuroprotection in Stroke -- Introduction. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Neuroprotection and the RAS. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Renin-angiotensin system. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Steckelings, U. Muscha. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Souza dos Santos, Robson Augusto. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Unger, Thomas |
| Title | The Protective Arm of the Renin Angiotensin System (RAS) |
| Place, publisher, and date of publication | San Diego : Elsevier Science & Technology,c2015 |
| International Standard Book Number | 9780128013649 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=2030662">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=2030662</a> |
| Public note | Click to View |
No items available.